Conteltinib

DB21262InvestigationalSmall molecule

Conteltinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Conteltinib is a tyrosine kinase inhibitor. Conteltinib is under investigation in clinical... Conteltinib is under investigation in clinical trial NCT06970132 (Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation).

Mechanism: Pharmacologically active on ALK tyrosine kinase receptor, Insulin-like growth factor 1 receptor, and Protein-tyrosine kinase 2-beta
Curator reviewed
Formula / weight: C₃₂H₄₅N₉O₃S · 635.83 g/mol (avg)

Resolves to

Compound

UNIIURX2UMQ8XVCAS1384860-29-0ChEMBLCHEMBL3899477ChEBI755967PubChem89860551

Structure

InChIKeyNPJCURIANJMFEO-UHFFFAOYSA-NSMILESCOC1=C(NC2=NC(NC3=C(C=CC=C3)S(=O)(=O)NC(C)C)=C3CCNC3=N2)C=CC(=C1)N1CCC(CC1)N1CCN(C)CC1

Targets

Q9UM73ALKP08069IGF1RQ14289PTK2BQ05397PTK2

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

20+ReferencesStructured and connected to the statements they support

Which drugs share a target with Conteltinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account